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Abstract: The evaluation of new prognostic factors that can be targeted in ovarian cancer diagnosis
and therapy is of the utmost importance. Galectins are a family of carbohydrate binding proteins
with various implications in cancer biology. In this study, the presence of galectin (Gal)-8 and
-9 was investigated in 156 ovarian cancer samples using immunohistochemistry (IHC). Staining
was evaluated using semi-quantitative immunoreactivity (IR) scores and correlated to clinical and
pathological data. Different types of galectin expression were compared with respect to disease-free
survival (DFS) and overall survival (OS). Gal-8 served as a new positive prognostic factor for the
OS and DFS of ovarian cancer patients. Gal-9 expression determined the DFS and OS of ovarian
cancer patients in two opposing ways—moderate Gal-9 expression was correlated with a reduced
outcome as compared to Gal-9 negative cases, while patients with high Gal-9 expression showed the
best outcome.
Keywords: galectin-8; galectin-9; immunochemistry; ovarian cancer; prognostic factor; disease-free
survival; overall survival
1. Introduction
Ovarian cancer is the fifth leading cause of cancer death among women of all ages [1]. Due to
its frequent diagnosis in advanced stages, characterized by a wide cancer dissemination into the
peritoneum and the acquisition of chemo resistance after treatment [2], ovarian cancer displays 5-year
relative survival rates of less than 50% [3]. Ovarian cancer management lacks effective screening
methods and specific treatment options. As prognosticators in ovarian cancer, the histological subtype,
disease stage at diagnosis, extent of residual disease after surgery, and volume of ascites can be used [4].
However, except for breast cancer gene (BRCA) status, no biological prognostic factor is commonly
considered [4]. Various studies have attempted to introduce new prognostic factors in ovarian cancer,
and for several proteins a prognostic value independent of clinical parameters has been detected.
However, so far none of them can be applied in ovarian cancer therapy or diagnosis. Hence, there is a
tremendous need for the evaluation of new prognostic factors that can be targeted in ovarian cancer.
In 1994 the galectin (Gal) family was described as group of proteins sharing a binding affinity
for β-galactosides, with significant similarity in the carbohydrate- recognition domain (CRD) [5,
6]. Since then, the galectin family has grown in members. In total, 10 different galectins (Gal-1–4,
Gal-7–10, Gal-12, and Gal-13) are known to be present in humans [7]. According to the arrangement
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of CRDs, galectins can be subdivided into three groups. Prototype galectins contain a single CRD,
often forming homodimers, while tandem-repeat galectins contain two CRDs connected by a linker
chain, and chimeric galectins (a group containing only member Gal-3) have a second N-terminal
domain connected to a single CRD [8]. In this study, we will focus on two tandem-repeat galectins,
Gal-8 and -9. By binding β-galactosides on certain glyoproteins with their CRDs, galectins are known
to modulate cell–cell and cell–matrix interactions as well as intracellular pathways [6]. Galectins
have been discovered to play an important role in several diseases including cancer [9]. Several
mechanisms of tumor biology, also referred to as “hallmarks of cancer”, are known to be influenced
by galectins: enhanced proliferation, resistance to cell death, and induction of angiogenesis, as well
as tumor invasion and metastasis [7,10,11]. Therefore, galectin expression in cancer tissues of several
malignancies has been found to affect patients’ disease-free survival (DFS) or overall survival (OS).
For this reason, several studies assessed different galectins as prognostic survival markers, but thus far,
most efforts have been spent on Gal-1 and -3. However, Gal-8 and -9 have been evaluated as prognostic
markers in few cancer types. In triple-negative breast cancer, for instance, patients displaying Gal-8
expression in nuclei had significantly better DFS and OS [12]. Higher Gal-9 expression, on the other
hand, was associated with prolonged OS of gastric cancer patients [13].
In ovarian cancer, however, most previous studies focused on galectin-1, -3 and -7 as prognostic
factors [14–19]. Our group recently published an article in the international journal of molecular
sciences, presenting high tumor and stroma Gal-1 expression, as well as higher Gal-7 expression as
negative prognostic markers for OS of ovarian cancer patients, while nuclear Gal-3 expression was
correlated with a better OS [20]. In fact, to our knowledge there is only one very recent study on Gal-8
and Gal-9 in ovarian cancer [21]. In this study, high epithelial Gal-8 expression was associated with the
acquisition of chemo resistance. However, no correlation with DFS or OS was observed. In the same
study, the Gal-9 expression that was observed in “cytosolic or perinuclear puncta”, was correlated with
poor OS. However, this special Gal-9 expression was not associated with altered DFS. Cytoplasmic
Gal-9 expression, however, showed no association to either DFS or OS. In general, with a 5-year
follow-up time, all of the observations were limited to a rather short period of observation and the
analysis was performed in a collective of only high-grade serous ovarian cancer samples, with their
prognostic role in other than subtypes remaining elusive. Summing up, there are a limited number of
studies on Gal-8 and -9 in ovarian cancer and several aspects of their prognostic features still remain to
be elucidated.
Therefore, in this study, we evaluated the prognostic influence of Gal-8 and -9 in patients with
epithelial ovarian cancer using immunohistochemistry and analyzed correlations to each other and
to clinical and pathological parameters. We hypothesize that Gal-8 and -9 are prognostic for overall
survival in ovarian cancer patients. Since it is known that galectin function and their effect on patients’
survival can be determined by expression in the nucleus or cytoplasm of cancer cells as well as the
peritumoral stroma, we paid attention to the specific location of galectin expression in our analysis.
2. Results
2.1. In Silico Analysis of Gal-8 and -9 Expression in Normal Ovarian Tissues and Ovarian Cancer
The human protein atlas (available at www.proteinatlas.org) was used to analyze Gal-8 and -9
expression in normal ovarian tissues as well as ovarian cancer tissues [22]. In ovarian stroma cells,
Gal-8 (human Gal-8 gene, LGALS8) was not detected via antibody staining. However out of 12 ovarian
cancer tissues, 8 showed medium Gal expression. For Gal-9 (human Gal-9 gene, LGALS9), out of
12 ovarian cancer patients, 3 showed medium Gal-9 expression and 5 patients showed low Gal-9
expression. In normal ovarian tissues, Gal-9 was found to have low expression in ovarian stromal
cells. According to this, both Gal-8 and Gal-9 seem to be altered in ovarian cancer compared to normal
ovarian tissues. This further motivated us to specify Gal-8 and -9 expression in ovarian cancer tissues
using immunochemistry.
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2.2. Gal-8 is a Positive Prognostic Factor for OS and DFS in Ovarian Cancer Patients
Galectin-8 staining could be evaluated in 143 ovarian cancer samples. Gal-8 expression occurred
predominantly in the cytoplasm and nuclei of ovarian cancer cells but not in the peritumoral stroma
(Figure 1). In total, 96 cases (67.1%) showed a high Gal-8 expression in the cytoplasm (immunoreactivity
score, IRS > 1), while in 47 specimens (32.9%), only low Gal-8 expression was observed (IRS ≤ 1).
The median IRS of Gal-8 staining in the cytoplasm was 3. According to chi-squared statistics, low Gal-8
expression in the cytoplasm correlated with lymph node metastasis as well as a higher International
Federation of Gynecology and Obstetrics (FIGO) stage (p = 0.019, p = 0.033, respectively) and (Table 1).
In 70 of the samples (51.4%) Gal-8 positive nuclei were observed, while 74 specimens (48.6%) did not
present with nuclear Gal-8 staining. Positive nuclear Gal-8 staining was more often observed in lower
FIGO stages (p = 0.011) and (Table 1). Besides, no other correlation of nuclear Gal-8 expression and
clinical or pathological data was observed.
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Figure 1. Detection of galectin-8 and -9 using immunohistochemistry (IHC). Gal-8 staining (A–C) and
Gal-9 staining (D–F) was predominantly present in the cytoplasm of ovarian cancer cells but not in the
peritumoral stroma. Representative photomicrographs are shown. There is a 10×magnification for
the outer pictures and 25× for the inserts. Scale bar in (A) equals 200 µm (outer pictures) and 100 µm
(inserts). Gal: galectin.
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Table 1. Gal-8 and -9 staining correlated with clinical and pathological data.
Gal-8 Expression (Cytoplasm) p-Value Gal-8 Expression (Nucleus) p-Value Gal-9 Expression (Cytoplasm) p-Value
Low High Negative Positive Negative Moderate High
Histology
Serous 40 62 NS 54 48 NS 24 71 9 0.024
Clear cell 2 9 3 8 1 10 0
Endometrioid 2 17 8 11 6 10 5
Mucinous 3 8 5 7 1 6 4
Tumor Stage
pT1 10 26 NS 14 23 NS 8 20 9 0.018
pT2+ 37 69 55 51 24 77 8
Lymph node
pN0/ pNX 25 70 0.019 43 53 NS 26 61 12 NS
pN1 22 26 27 21 6 36 6
Distant Metastasis
pM0/pMX 45 94 NS 68 72 NS 32 92 17 NS
pM1 2 2 2 2 0 5 1
Grading
G1 7 26 NS 13 21 NS 7 19 8 0.006
G2+ 37 62 53 46 24 72 5
FIGO
I/ II 8 33 0.033 14 28 0.011 6 25 11 0.002
III/ IV 37 60 55 42 25 69 6
Age
≤60 years 24 51 NS 32 43 NS 10 52 17 <0.001
>60 years 23 45 38 31 22 45 1
TNM staging was accomplished according to the Union for International Cancer Control (UICC); pT1 = tumor stage 1; pT2+ = tumor stage 2 or higher; pN0 = lymph node stage 0;
pNX = lymph node stage not evaluated; pN1 = lymph node stage 1; pM0 = distant metastasis stage 0; pMX = distant metastasis not evaluated; pM1 = distant metastasis stage 1;
G1 = grade 1; G2+ = grade 2 or higher; NS = Not significant (p > 0.05).
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Different groups of Gal-8 expression were compared using Kaplan-Meier analysis (Figure 2).
Patients presenting with high Gal-8 expression showed a significantly better overall survival and
disease-free survival (p = 0.024, p = 0.018, respectively). Nuclear Gal-8 expression had no significant
influence on overall or disease-free survival. In multivariate analysis, Gal-8 staining served as a
prognostic factor independent of clinical and pathological variables (Table 2).
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Figure 2. Survival times of patient groups with different galectin-8 and -9 expression levels were
compared. Patients with high Gal-8 expression in the cytoplasm showed better progression-free (A)
and overall survival (B) compared to patients without o with low Gal-8 expressio . Cases with a
moderate Gal-9 expression in the cytoplasm displayed a educ d progression-free (C) and overall
survival (D) compared to Gal-9 negative cases. However, patients with high Gal-9 expression showed
the best progression-free (C) and overall survival (D). Galectin-8 and -9 expression was determined in
the cytoplasm of cancer cells using IHC and immunoreactivity (IR) scores. Survival times were plotted
as Kaplan–Meier graphs. Graph shows the percentage of living patients (vertical axis) in dependence
of time (horizontal axis). Patients without reported death who exited the study before the observation
period ended were censored by the software. Censoring events have been marked in the graphs.
Table 2. Multivariate analysis.
Covariate Coefficient (bi) HR Exp (bi)
95% CI p-Value
Lower Upper
Histology −0.005 0.995 0.989 1.002 0.135
Grading 0.614 1.848 1.342 2.544 <0.001
FIGO 0.763 2.144 1.503 3.058 <0.001
Patients’ age (≤60 vs. >60 years) 0.737 2.089 1.265 3.447 0.004
Gal-8 staining (low vs. high) −0.487 0.615 0.388 0.973 0.038
Gal-9 staining (neg. vs. low vs. high) 0.687 1.988 1.257 3.145 0.003
HR = hazard ratio; CI = confidence interval.
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2.3. Gal-9 Expression Determines DFS and OS of Ovarian Cancer Patients in Two Different Ways
Staining for galectin-9 was assessed in 147 ovarian cancer samples using IR scores. Gal-9 staining
was mostly present in the cytoplasm of ovarian cancer cells, but not the nuclei or the peritumoral
stroma. Throughout the panel a median IRS of 3 was observed. In total, 32 cases (20.5%) were Gal-9
negative (IRS = 0), 79 cases (50.6%), however, presented with moderate Gal-9 staining (1 ≥ IRS ≥ 6)
and in 36 cases (24.5%) high Gal-9 expression (IRS > 6) was observed. Gal-9 staining showed different
distribution in different histological subtypes (Table 1). Cases with high Gal-9 expression presented
more often with low tumor stage, lower grading, early FIGO stage, and younger age. The majority
of Gal-9 negative cases, however, showed a high tumor stage, higher grading, advanced FIGO stage,
and older age (Table 1).
Using Kaplan-Meier analysis, different groups of Gal-9 expression showed significant differences
in overall and disease-free survival. Cases with a moderate Gal-9 expression (1 ≥ IRS ≥ 6) displayed a
reduced progression-free and overall survival compared to Gal-9 negative cases (IRS = 0). However,
the small group of patients presenting with a high Gal-9 expression (IRS > 6) showed the best
progression-free (C) and overall survival (D). In multivariate analysis, this correlation proved to
be independent of clinical and pathological variables, together with grading, FIGO, patients’ age and
Gal-8 expression.
2.4. Correlation Analysis
A correlation analysis between IR scores of Gal-8 and Gal-9 staining in the cytoplasm was
performed. Results are shown in Table 3. We observed a rather weak, but highly significant correlation
between cytoplasmic Gal-8 and Gal-9 staining (p < 0.001).
Table 3. Correlation analysis.
Gal-9 Cytoplasm
Gal-8 cytoplasm
cc 0.464
p <0.001
n 142
IR scores for Gal-8 and -9 staining were correlated using Spearman’s correlation analysis. cc = correlation coefficient,
p = two-tailed significance, n = number of patients.
3. Discussion
According to our data, high Gal-8 expression in the cytoplasm of cancer cells is a novel positive
prognostic factor for DFS and OS in ovarian cancer patients. Cytoplasmic Gal-9 expression, however,
determines the DFS and OS of ovarian cancer patients in two opposing ways: On one hand,
moderate Gal-9 expression correlates with a reduced overall and disease-free survival, compared to
Gal-9-negative cancers, while high Gal-9 expression correlated with the best outcome. Stromal Gal-8
or -9 was not observed in ovarian cancer samples and nuclear expression does not seem to play an
important role for survival of ovarian cancer patients.
In 1995, Gal-8 was cloned for the first time from a rat liver cDNA expression library [23]. Later,
a homolog gene was detected in the human prostate adenocarcinoma cell line LNCaP, that was identified
as prostate carcinoma tumor antigen-1 (PCTA-1). Also, altered Gal-8 expressed was found in prostate
carcinomas compared to normal prostate and benign prostatic hypertrophy [24]. Several alternative
splicing variants have been reported in Gal-8 mRNA processing [25]. In total, seven different isoforms
of Gal-8 are encoded by the human Gal-8 gene (LGALS8). Three of them belong to the tandem-repeat
galectin group and four to the prototype group with only one CRD. However, prototype isoforms of
Gal-8 were not found at the protein level [26]. Nevertheless, rather than as a single protein, galectin-8
should be regarded as a discrete subfamily among all galectins. To our knowledge, there are no
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antibodies available to target specific isoforms of galectin-8. Hence, immunohistochemistry is limited
to the observation of the total expression level of all galectin-8 isoforms. Whether different anti-Gal-8
antibodies have a higher affinity for certain Gal-8 isoforms remains elusive as well. However, this could
be a reason for different results evaluating Gal-8 as a prognostic factor using different antibodies in
immunohistochemistry [21]. This problem should be addressed in further experiments, e.g., using
Western blot analysis to determine the individual Gal-8 subtype expressed in ovarian cancer tissues.
Gal-8 has been found to contribute to several mechanism of tumor biology. Endothelial cell
migration and tube formation in vitro as well as angiogenesis in vivo has been demonstrated to be
induced by Gal-8 [27]. Cell adhesion in human non-small cell lung carcinoma cells (H1299) and rat
hepatoma cells (Fao) as well as Chinese hamster ovary (CHO-P) cells was affected by the presence
of Gal-8, either positively or negatively dependent on its concentration [28]. In glioblastoma cell line U87,
Gal-8 was shown to promote cell migration and proliferation and has been observed to prevent tumor
cell apoptosis [29]. However, none of these effects have been examined in ovarian cancer, and further
studies are required to explain the role of Gal-8 in ovarian cancer biology.
One of the first descriptions of Galectin-9 was in 1997, after which it was cloned and identified as
a tumor antigen in Hodgkin’s lymphoma [30]. Since then, many implications of Gal-9 in cancer have
been reported [31]. In melanoma cells, galectin-9 was able to induce cell aggregation and apoptosis,
and down-regulation of Gal-9 was associated with distant metastasis [32]. Similarly, in breast cancer,
Gal-9 negative tumors were more likely to show distant metastasis and therefore correlated with an
unfavorable prognosis [33]. In both, melanoma and breast cancer, tumor cell adhesion has been found
to be influenced by Gal-9 expression [32,34]. Furthermore, changing Gal-9 expression was discovered
during endothelial cell activation, implying a function in angiogenesis [35]. However, best studied
role of Gal-9 is in immunity and inflammation. Most prominent mechanism here is the binding of
Gal-9 to TIM3, a T cell-specific surface molecule, leading to intracellular calcium flux, aggregation, and
apoptosis of T-helper type 1 cells [36]. Similarly, in CD8+ cytotoxic T-cells, Gal-9 was able to induce
apoptosis in vitro and vivo, inhibiting the immune response to alloantigen of a skin graft [37]. The same
mechanism can be implicated in the acquaintance of tumor immunity. Furthermore, Gal-9 induced the
differentiation of naive T cells to T regulatory (T reg) cells, decreasing the number of CD4(+) TIM3(+)
T cells and increasing the number of T reg cells in the peripheral blood of a mouse model [38]. T reg
cells, however, are known to suppress the antitumor immune response and therefore enable the tumor
immune escape [39]. In line with this, in ovarian cancer, a higher number of T reg cells in lymphoid
aggregates surrounding the tumor were associated with significantly reduced patient survival [40].
Summing up, the role of Gal-9 in cancer immunity implicates a reduced survival of patients with
Gal-9 expressing cancers, while its functions in apoptosis, cancer cell adhesion, and metastasis could
explain a better outcome in Gal-9 expressing ovarian cancers. Both taken together could serve as an
explanation for the two opposing ways in which Gal-9 determined the survival of ovarian cancer
patients in this study.
Similar to Gal-8, several splice variants have been reported for Gal-9 [31]. Again, varying
antibody affinity to different Gal-9 isoforms could explain contradictory results in different studies [21].
Furthermore, heterogeneity in Gal-9 splice variants could explain the complex effects of Gal-9
expression on patients’ survival, which is described in literature, but was also observed in this study.
Assuming different Gal-9 isoforms can realize different functions in cancer biology, patient survival
could be affected by different Gal-9 isoforms in opposing ways. However, since these considerations
are rather speculative, further studies are required to address this problem.
4. Materials and Methods
4.1. Patients
Tissue micro arrays (TMAs) were constructed from a collective of formalin-fixed, paraffin-embedded
(FFPE) ovarian cancer samples obtained from a collective of 156 female patients who underwent
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surgery at the Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Germany
between 1990 and 2002. No patient had received chemotherapy before surgery. Four histological
subtypes were included into the panel (serous (n = 110), endometrioid (n = 21), clear cell (n = 12),
and mucinous (n = 13)). Experienced gynecological pathologists (E.S., D.M.) performed tumor grading
(G1 (n = 38), G2 (n = 53), G3 (n = 53)) according to WHO. TNM classification (T = tumor, N = lymph
nodes, M = metastasis) was performed according to the Union for International Cancer Control (UICC).
Extent of the primary tumor (T1 (n = 40), T2 (n = 18), T3 (n = 93), T4 (n = 4)), lymph node involvement
(N0 (n = 43), N1 (n = 52) and distant metastasis (M0 (n = 3), M1 (n = 6) was evaluated. FIGO stage was
determined (I (n = 35), II (n = 10), III (n = 103), IV (n = 3)) according to the criteria of the International
Federation of Gynecology and Obstetrics (FIGO). Patient follow up data was received from the Munich
Cancer Registry. Median patients’ age was 62± 12 years with a range between 31 and 88 years. During
the study 104 deaths have been observed with a mean overall survival of 3.2 ± 3.0 years.
4.2. Immunohistochemistry
TMA slides were stained using immunohistochemistry as previously described [16]. All sections
were dewaxed in xylol for 20 min, before endogenous peroxidase was quenched with 3% hydrogen
peroxide (Merck, Darmstadt, Germany). Next, slides were rehydrated in a descending series of alcohol
(100%, 75%, and 50%) and heat-induced antigen retrieval was performed by cooking in sodium citrate
buffer (0.1 mol/L citric acid/0.1 mol/L sodium citrate, pH 6.0) in a pressure cooker for 5 min. Tissues
were blocked with Blocking Solution (Reagent 1; ZytoChem Plus HRP Polymer System (Mouse/Rabbit);
Zytomed Systems GmbH, Berlin, Germany) for 5 min at room temperature (RT). Then, specimens were
incubated with Anti-Gal-8 (rabbit, monoclonal, Abcam, Cambridge, UK) at a final concentration of
10 µg/mL (1:100 dilution) in phosphate buffered saline (PBS) for 1 h at RT, and Anti-Gal-9 (rabbit,
polyclonal, Abcam, Cambridge, UK) at a final concentration of 3.34 µg/mL (1:300 dilution) in PBS
overnight (16 h) at 4 ◦C. Afterwards, slides were incubated with post-block reagent (Reagent 2) (Zytomed
Systems GmbH, Berlin, Germany) for 20 min at RT and HRP-Polymer (Reagent 3) (Zytomed Systems
GmbH, Berlin, Germany) for 30 min at RT. After each incubation, slides were washed in PBS twice
for 4 min. Visualization reaction was performed with 3,3′-diaminobenzidine chromagen (DAB; Dako,
Glostrup, Denmark) and stopped after 2 min in tap water. Counterstaining was performed with Mayer
acidic hematoxylin. Specimens were dehydrated in an ascending series of alcohol (50%, 75%, and 100%)
followed by xylol. Tissue sections, incubated with PBS instead of a primary antibody, were used as a
negative control. Tissue samples of colon mucosa served as a positive control. Staining results were
received using a semi-quantitative method analog to the immunoreactivity score. Staining for Gal-8 and -9
was evaluated in the cytoplasm of ovarian cancer cells. The predominant staining intensity (0 = negative,
1 = low, 2 = moderate, and 3 = strong) and the percentage of stained cells (0 = 0%, 1 = 1–10%, 2 = 11–50%,
3 = 51–80%, and 4 = 81–100% stained cells) were assessed and multiplied resulting in values of the IRS.
For survival analysis, Gal-8 was grouped into low (IRS≤ 1) and high expression cases (IRS > 1). Gal-9 was
divided into negative (IRS = 0), moderate (1 ≥ IRS ≥ 6) and high (IRS > 6) expression.
4.3. Statistical Analysis
Statistical data was processed using SPSS 23.0 (v23, IBM, Armonk, New York, NY, USA)
statistic software. Chi-squared statistics were used to test for correlation to clinical and pathological
variables. Correlations between staining results were calculated using spearman’s correlation analysis.
Kaplan–Meier curves and the log-rank test (Mantel–Cox) were used for survival analysis. Data are
presented with the mean ± standard deviation. Significance was assumed for p < 0.05.
4.4. Ethics Statement
The current study was approved by the Ethics Committee of the Ludwig Maximilians University,
Munich, Germany (approval number 227-09) on 30 September 2009. All tissue samples used for
this study were obtained from left-over material from the archives of LMU Munich, Department
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Gynecology and Obstetrics, Ludwig-Maximilians University, Munich, Germany, initially used for
pathological diagnostics. The diagnostic procedures were completed before the current study was
performed. During the analysis, the observers were fully blinded for patients’ data. The study was
approved by the Ethics Committee of LMU Munich. All experiments were performed according to the
standards of the Declaration of Helsinki (1975).
5. Conclusions
We were able to show that Gal-8 expression is a positive prognostic factor for overall and
disease-free survival of ovarian cancer patients, while Gal-9 expression determines overall and
disease-free survival in two different ways: Moderate Gal-9 expression correlates with a reduced
survival, compared to Gal-9 negative cases, while patients with high Gal-9 expression showed the
best outcome.
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Abbreviations
Gal Galectin
IHC Immunohistochemistry
IRS Immunoreactivity score
DFS Disease-free survival
OS Overall survival
BRCA Breast cancer gene
CRD Carbohydrate-recognition domain
LGALS8 Human Gal-8 gene
LGALS9 Human Gal-9 gene
FIGO Fédération Internationale de Gynécologie et d’Obstétrique
UICC Union for International Cancer Control
PCTA-1 Prostate carcinoma tumor antigen-1
CD8 cluster of differentiation 8
CD4 cluster of differentiation 4
TIM3 T-cell immunoglobulin and mucin-domain containing-3
T reg T-regulatory
TMA Tissue micro array
FFPE Formalin-fixed paraffin-embedded
WHO World Health Organization
TNM T = tumor, N = lymph nodes, M = metastasis
PBS phosphate buffered saline
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